Table 2.

Central macular thickness (measured in µm) at baseline and at benchmark follow-up visits in both the groups

	Baseline	1st month	3rd month	6th month	12th month
Aflibercept group	465.29±33.7 (411–535)	365.4±72.2 (256–499)	370.54±83.6 (250–527)	391.7±85.8 (245–536)	360.8±85.7 (265–501)
Ranibizumab group	471.5±34.4 (402–516)	388.06±77.3 (245–519)	394.3±84.8 (246–578)	360.1±74.4 (236–529)	387.3±87.8 (253–522)
P-value	0.65	0.2	0.24	0.1	0.2

Note: The data in this table are presented as mean ± SD (range).